You are here

Alpha/Beta L-Nucleosides--Synthesis & Biological Action

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 CA65432-1,
Agency Tracking Number: 24936
Amount: $80,903.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1994
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
14785 Omicron Drive, Suite 100
San Antonio, TX 78245
United States
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Kirupathevy Shanmuganatha
 (210) 677-6000
Business Contact
Phone: () -
Research Institution
N/A
Abstract

This grant will study the feasibility of developing convenient, cost-effective methods of synthesisfor L-sugar nucleoside and nucleotide analogue chemotherapeutic agents and to investigate theirphosphorylation and uptake by malignant cells in tissue culture. L-sugar-based therapeutic agents havepotential as anticancer, antiviral, and antiparasitic drugs. During Phase I, we will (a) develop pilot scalesynthesis of the L-series sugars L-ribose and L-deoxyribose as the building blocks for L-nucleosides/nucle-otides from a common synthetic precursor L-erythuronolactone; (b) synthesize both the alpha- andbeta-isomers of the L-ribonucleosides and L-deoxyribonucleosides derived from the bases adenine,cytosine and 5-fluorouracil; (c) synthesize the corresponding 5'-nucleotides of the compounds in (b) andthe 5'-triphosphates; (d) establish tissue culture assays to measure intracellular phosphorylation of thenucleoside in (b) by kinases; and (e) evaluate the in vitro anti-tumor activity of the synthesizedL-nucleosides.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government